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Abstract
-Galactosylceramide (-GalCer) is a glycolipid that stimulates natural killer T cells to produce
both T helper (Th) 1 and Th2 cytokines. This property enables -GalCer to ameliorate a wide
variety of infectious, neoplastic, and autoimmune diseases; however, its effectiveness against
any one disease is limited by the opposing activities of the induced Th1 and Th2 cytokines.
Here, we report that a synthetic C-glycoside analogue of -GalCer, -C-galactosylceramide
(-C-GalCer), acts as natural killer T cell ligand in vivo, and stimulates an enhanced Th1-type
response in mice. In two disease models requiring Th1-type responses for control, namely malaria
and melanoma metastases, -C-GalCer exhibited a 1,000-fold more potent antimalaria activity
and a 100-fold more potent antimetastatic activity than -GalCer. Moreover, -C-GalCer
consistently stimulated prolonged production of the Th1 cytokines interferon- and interleukin
(IL)-12, and decreased production of the Th2 cytokine IL-4 compared with -GalCer. Finally,
-C-GalCer’s enhanced therapeutic activity required the presence of IL-12, which was needed
to stimulate natural killer cells for optimal interferon- production, but did not affect IL-4.
Overall, our results suggest that -C-GalCer may one day be an excellent therapeutic option
for diseases resolved by Th1-type responses.
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Introduction
Natural killer T cells (NKT cells) are a unique population
of lymphocytes that coexpress markers of NK cells along
with a semiinvariant TCR. In mice, the TCR of most
NKT cells consists of an invariant V chain encoded by the
V14 and J18 gene segments paired with a variable set of
V chains encoded mainly by the V8.2, V7, or V2
gene segments. This TCR enables NKT cells to recognize
the MHC class I–like molecule CD1d, which is capable of
presenting hydrophobic molecules such as lipids and hydrophobic peptides to NKT cells (1, 2).
Thus far, only a few molecules have been shown to activate
NKT cells. Of these, -galactosylceramide (-GalCer), a
glycolipid originally derived from a marine sponge extract,
is the best characterized. When NKT cells recognize
-GalCer presented by APCs in the context of CD1d,
they respond by rapidly producing large amounts of both
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IFN- and IL-4, and disappearing within 6 h after activation (2–5). In addition, proliferation of and IFN- production by NK cells also occurs after NKT cell activation
by -GalCer (2, 4, 6, 7), as do bystander activation of
conventional T cells (2, 4, 8) and IL-12 production by
APCs (2, 4, 9–11). -GalCer’s ability to stimulate large
amounts of both IFN- and IL-4 endows it with therapeutic efficacy in various disease models. IFN- stimulated by -GalCer enables the glycolipid to combat a wide
variety of infectious diseases, including malaria and hepatitis B,
as well as various tumor metastases including melanoma
metastases to the lungs and liver. IL-4 stimulated by -GalCer allows the glycolipid to ameliorate a number of different autoimmune diseases, including autoimmune type 1 diabetes and autoimmune encephalomyelitis (4).
Despite -GalCer’s therapeutic efficacy against a wide
variety of disease states, a recent paper indicates that -GalAbbreviations used in this paper: -C-GalCer, -C-galactosylceramide;
-GalCer, -galactosylceramide; ICCS, intracellular cytokine staining;
NKT cell, natural killer T cell.
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Cer’s concomitant stimulation of both IFN- and IL-4
limits its ability to maximally combat any one disease due
to the antagonistic activities of the two cytokines (12). Recently, a synthetic analogue of -GalCer possessing a truncated sphingosine chain was shown to stimulate IL-4 production only, and better protect mice from autoimmune
encephalomyelitis, showing that small changes in the molecule can stimulate altered, but useful phenotypes (13). In
this regard, we synthesized a C-glycoside analogue of
-GalCer (-C-galactosylceramide [-C-GalCer]) bearing
a single change: the replacement of the glycosidic O by CH2.
This alteration is expected to render the analogue resistant
to -galactosidase catabolism in vivo (14, 15). In addition,
the substitution of the glycosidic O, a polar hydrogen bond
acceptor, by CH2, a nonpolar group, might influence the
quality of the NKT cell response to the CD1d–glycolipid
complex in a manner different than -GalCer. Given these
differences, we were curious to see if our analogue exhibited altered activity in vivo compared with -GalCer.

Materials and Methods
Glycolipids. -GalCer [(2S,3S,4R)-1-O-(-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol] was synthesized by Kirin Brewery. The stock solution was dissolved in a
0.5% polysorbate-20 (Nikko Chemical), 0.9% NaCl solution at a
concentration of 200 g/ml, and diluted in PBS just before injection into mice. -C-GalCer [(2S,3S,4R)-1-CH2-(-d-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol] was
synthesized as described in the Results section. The stock solution
was originally dissolved in 100% DMSO at a concentration of 1
mg/ml. Before injection into mice, it was diluted to a concentration of 200 g/ml in a 0.5% polysorbate-20 (Nikko Chemical),
0.9% NaCl solution, and diluted in PBS just before injection into
mice.
Mice. 6–8-wk-old female BALB/c mice were purchased
from the National Cancer Institute. 6–8-wk-old female C57BL/6
mice were purchased from the Jackson Laboratory. CD1d-deficient mice were a gift from L. Van Kaer (Vanderbilt University
School of Medicine, Nashville, TN). J18-deficient mice were a
gift from T. Nakayama and M. Taniguchi (Chiba University
School of Medicine, Chiba-shi, Chiba, Japan). IFN-–deficient
mice of BALB/c background were purchased from the Jackson
Laboratory. IFN- receptor–deficient mice were bred and maintained in our animal facility (New York University School of
Medicine). IL-12p40–deficient mice of BALB/c and C57BL/6
backgrounds were purchased from the Jackson Laboratory. All
mice were maintained in our animal facility (New York University School of Medicine) under pathogen-free conditions.
Parasites and Their Use for Challenge. Plasmodium yoelii
(17XNL strain) was maintained by alternate cyclic passages in
Anopheles stephensi mosquitoes and Swiss Webster mice. Sporozoites obtained from dissected salivary glands of infected mosquitoes 2 wk after their infective blood meal were used for challenge of the mice. Challenge of mice to determine the
development of liver-stage malaria infection was performed by
an intravenous injection of 10,000 viable sporozoites into the tail
vein. The outcome of the challenge was determined 40–42 h
later by measuring the parasite burden in the livers of the mice
using a quantitative real-time RT-PCR method (16). Challenge
of mice to determine the development of blood-stage malaria in-
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fection was performed by an intravenous injection of 75 viable
sporozoites into the tail vein. Starting 4 d after challenge, daily
peripheral blood smears were obtained from each mouse and examined microscopically for the presence of blood stage parasites
until day 17 after challenge. Mice were considered positive for
parasitemia if at least one blood-stage parasite was observed during the time of examination.
Determination of Malaria Liver Stage Development. The degree
of liver-stage development in challenged mice was determined by
quantifying the amount of P. yoelii–specific 18S rRNA molecules
in the livers of the mice by way of a recently developed real-time
RT-PCR technique (16). In brief, a 2-g sample of total RNA
prepared from the livers of challenged mice was reverse transcribed, and an aliquot of the resulting cDNA (133 ng) was used
for real-time PCR amplification of P. yoelii 18S rRNA sequences. This amplification was performed in a sequence detection system (model GeneAmp™ 5700; PE Applied Biosystems).
For this purpose, we used primers 5-GGGGATTGGTTTTGACGTTTTTGCG-3 (54 nM) and 5-AAGCATTAAATAAAGCGAATACATCCTTAT-3 (60 nM) together with the dsDNA-specific dye SYBR Green I incorporated into the PCR
reaction buffer (PE Biosystems) to detect the PCR product generated. The temperature profile of the reaction was 95C for 10
min followed by 40 cycles of denaturation at 95C for 15 s and
annealing/extension at 60C for 1 min.
Determination of Melanoma Lung Metastases. The development of melanoma lung metastases in C57BL/6 mice was determined by first challenging mice intravenously with syngeneic B16
melanoma cells suspended in DMEM supplemented with 10%
FCS. 2 or 3 wk after challenge the mice were killed, the lungs
were removed, and the number of metastatic nodules were
counted as described previously (17).
Determination of Serum Cytokine Concentrations. The serum
concentrations of IFN- and IL-4 were measured 2, 6, 12, 24, 48,
and 72 h after treatment with -GalCer, -C-GalCer, or nothing
by way of a sandwich ELISA (eBioscience). The serum concentrations of IL-12p70 were also measured at 2, 6, 12, 24, 48, and 72 h
after treatment by way of a sandwich ELISA (BD Biosciences).
Flow Cytometry and Intracellular Cytokine Staining (ICCS).
Freshly isolated liver lymphocytes from C57BL/6 mice were first
incubated for 15 min at 4C with unlabeled anti–mouse FcIII/II
receptor mAb clone 2.4G2 (BD Biosciences) in staining buffer (PBS
containing 1% FBS and 0.1% NaN3). Next, the cells were surface
stained with PE-labeled anti-NK1.1 mAb clone PK136 (BD Biosciences) and FITC-labeled anti-CD3 mAb clone 145-2C11 (BD
Biosciences) in staining buffer for 30 min at 4C. After two washes
in staining buffer, the cells were fixed, permeabilized using Cytofix/
Cytoperm Plus™ (BD Biosciences), and stained for intracellular
IFN- using allophycocyanin-labeled anti–IFN- mAb clone
XMG1.2 (BD Biosciences) or for intracellular IL-4 using allophycocyanin-labeled anti–IL-4 mAb clone 11B11 (BD Biosciences) according to the manufacturer’s protocol. Finally, the stained cells
were analyzed using a FACSCalibur™ instrument (Becton Dickinson) with CELLQuest™ software (Becton Dickinson).

Results
Synthesis of -C-GalCer. Our synthesis of -C-GalCer proceeded by linking a phytosphingosine homologated by one carbon to d-galactose by way of the
Ramberg–Backlund protocol (18, 19). The necessary
-anomeric configuration of the C-glycoside was estab-
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Figure 1. Synthesis and structure of -C-GalCer. (a) Overview
of the pathway used to synthesize
-C-GalCer. The Ramberg–
Backlund link-up was performed
and the -configuration was established. Protecting groups were
removed and the C-26 fatty
amide was installed. (b) Structural
comparison of -C-GalCer and
-GalCer, showing the main
differences between the two
molecules. Glycoside CH2 is
nonpolar and hydrophobic; it
repels hydrogen bond donors. In
contrast, glycoside oxygen is polar
and the electron pairs can form
hydrogen bonds with N–H and
O–H donors.

lished using an intramolecular hydride donor methodology. The synthetic route for the homophytosphingosine
side chain followed known procedures (20, 21), and the
source of chirality for the amine was l-homoserine (as
compared with l-serine for the phytosphingosine parent).
The necessary hydroxyls were established by a Sharpless
dihydroxylation. In the final step, after the -galacto-Cphytosphingosine assembly was complete, and all protecting groups had been removed, the fatty amide chain was
introduced using p-nitrophenyl hexadecanoate (22) as the
acylating agent to form the final product. Purification was
done by flash chromatography on silica gel eluting with
CHCl3/MeOH (4:1). Mass spectroscopy and 1H nuclear
magnetic resonance analysis of the fully acylated compound confirmed that it was the desired C-glycoside analogue of -GalCer, which we have given the trivial name
CRONY-101 (Fig. 1).
-C-GalCer Protects Mice from the Liver Stages of Malaria in
a Manner Dependent on CD1d, V14 NKT Cells, and
IFN-. We showed previously that -GalCer, when administered to mice 2 d before challenge with plasmodial

sporozoites, suppressed development of malaria liver stages
in a manner dependent on both CD1d-restricted, V14
NKT cells and IFN-–IFN- receptor signaling (23). To
see if -C-GalCer exhibited a similar behavior, we injected
WT mice with either -GalCer or -C-GalCer 2 d before
challenge with live P. yoelii sporozoites, and measured the
degree of liver stage development using a quantitative realtime RT-PCR assay (16). Mice treated with either -GalCer or -C-GalCer showed virtually no liver stage development as compared with untreated control mice, showing
that -C-GalCer has in vivo antimalaria activity similar to
that of -GalCer (Fig. 2 a).
Next, to see if -C-GalCer’s antimalaria activity requires
the same determinants as -GalCer, we injected mice deficient in CD1d, J18 (formerly J281), IFN-, or IFN-
receptor with the analogue, and measured liver stage development. As with -GalCer, -C-GalCer was unable to
suppress P. yoelii liver-stage development in the absence of
these molecules (Fig. 2, b and c). Because both CD1d- and
J18-deficient mice lack V14 NKT cells (24, 25), our results show that -C-GalCer is a ligand for this cell type in

Figure 2. -C-GalCer protects
mice from malaria liver stages in
a manner dependent on CD1d,
V14 NKT cells, and IFN-. (a)
WT BALB/c mice were treated
intraperitoneally with 2 g of
either -C-GalCer or -GalCer
or with nothing 2 d before challenge with live P. yoelii sporozoites, and
checked for malaria liver stage development. (b) CD1d- or J18-deficient
mice were treated intraperitoneally with 2 g of either -C-GalCer or
-GalCer or with nothing 2 d before challenge with sporozoites, and
checked for malaria liver stage development. (c) IFN-– or IFN- receptor–
deficient mice were treated intraperitoneally with 2 g of either -C-GalCer
or -GalCer or with nothing 2 d before challenge with sporozoites, and
checked for malaria liver stage development. (a–c) The results are expressed
as the mean
SD of five mice. In all figures, the data represent one of
two or more experiments with similar results.
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Figure 3. -C-GalCer better
protects mice from malaria liver
stages and melanoma metastases
than -GalCer. (a) WT BALB/c
mice were treated intraperitoneally with different doses of
either -C-GalCer or -GalCer
or with nothing 3 d before challenge with live P. yoelii sporozoites, and checked for malaria
liver stage development. (b) WT
BALB/c mice were treated intraperitoneally with 100 ng of either
-C-GalCer or -GalCer or with
nothing at various times before
challenge with sporozoites, and
checked for malaria liver stage
development. (c) WT BALB/c
mice were injected intraperitoneally with 100 ng of either
-C-GalCer or -GalCer or
with nothing 3 d before challenge with live P. yoelii sporozoites. Mice were monitored daily
for the presence of blood stage
parasites. (d) WT C57BL/6 mice
were treated intravenously with
different doses of either -C-GalCer or -GalCer or with nothing 2 d before intravenous challenge with 5 104 syngeneic B16 melanoma cells. 3 wk later, the lungs were checked for
tumor metastases. (a, b, and d) The results are expressed as the mean SD of five mice. The images shown come from one representative mouse out of
five per group.

vivo. Moreover, the requirement of IFN-–IFN- receptor signaling indicates that -C-GalCer stimulates a Th1type response.
-C-GalCer Exhibits Enhanced Antimalaria Activity Compared with -GalCer. To see if a difference exists between
-C-GalCer and -GalCer, we compared both the dose
response and kinetic effect of the two glycolipids against
the liver stages of malaria. For the dose response, we treated
mice with various doses of either glycolipid 3 d before P.
yoelii sporozoite challenge, and measured liver stage development. We found that -C-GalCer exhibited a much
more potent antimalaria activity, with a dose of 1 ng -CGalCer slightly more potent than 1 g -GalCer (Fig. 3 a).
For the kinetic effect, we treated mice with an identical
dose of either glycolipid at different time points before
sporozoite challenge, and measured the liver stages. Here,
we also observed a striking difference, with -C-GalCer
exhibiting an extended antimalaria effect of up to 3 d
longer than -GalCer (Fig. 3 b).
To confirm the superior antimalaria effect of -C-GalCer, we assessed the ability of either glycolipid to prevent
blood stage malaria infection in mice challenged with live
sporozoites. When given 3 d before challenge, -C-GalCer completely protected 9 out of 10 mice from bloodstage malaria, whereas an identical dose of -GalCer protected 0 out of 10 mice, the same as untreated controls
(Fig. 3 c). Because sporozoite-induced blood-stage infection requires prior successful development of the liver
stages, these results corroborate the liver-stage data shown
earlier, and clearly show the superior effect of -C-GalCer
in vivo.
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-C-GalCer Exhibits Enhanced Activity against Melanoma
Metastases Compared with -GalCer. Because NKT cell–
mediated protection against the liver stages of malaria requires IFN-–IFN- receptor signaling, the enhanced activity we observed with -C-GalCer suggested it might be
superior in other disease models requiring Th1-type responses for control. One such model involves melanoma
metastases to the lungs, in which -GalCer–mediated inhibition requires an IFN- response initiated by NKT cells
(26). To see if -C-GalCer is better able to prevent such
metastases than -GalCer, we treated mice with various
doses of either glycolipid 2 d before intravenous challenge
with syngeneic melanoma cells, and 2 wk later checked the
lungs for the number of metastatic nodules that developed
(17). Parallel to our malaria results, -C-GalCer exhibited
a more potent antimetastatic response than -GalCer, with
1 ng -C-GalCer equal to 100 ng -GalCer (Fig. 3 d).
-C-GalCer Stimulates an Enhanced Th1-type Response in
Mice. The superior effect of -C-GalCer against both
malaria liver stages and melanoma metastases suggested it
might stimulate an enhanced Th1-type response in vivo
compared with -GalCer. To test this idea, we injected
mice with the same dose of either -C-GalCer or -GalCer, and at various time points afterwards obtained blood
samples for ELISA analyses of IFN-, IL-4, and IL-12
concentrations in the sera. For IL-4, both glycolipids stimulated peak concentrations 2 h after treatment; however,
-GalCer stimulated concentrations roughly four times
higher than -C-GalCer (Fig. 4 a). For IFN-, both glycolipids stimulated detectable levels starting at 2 h, but
-GalCer’s peak occurred 12 h after treatment, returning
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Figure 4. -C-GalCer stimulates an enhanced Th1-type response in vivo compared with -GalCer that depends on IL-12. (a) WT C57BL/6 mice
were treated intravenously with 1 g of either -C-GalCer or -GalCer or with nothing, and serum samples were obtained at the indicated time points
after injection for ELISA analyses of IL-4, IFN-, and IL-12 concentrations. (b) IL-12–deficient C57BL/6 mice were treated intravenously with 1 g of
either -C-GalCer or -GalCer or with nothing, and serum samples were obtained at the indicated time points after injection for ELISA analyses of IL-4
or IFN-. The data are expressed as the mean SD of two different dilutions of pooled sera.

to baseline by 24 h. In contrast, -C-GalCer’s peak occurred
24 h after treatment, returning to baseline by 48 h (Fig. 4
a). Finally, for IL-12, both glycolipids stimulated peak
concentrations 6 h after treatment; however, -C-GalCer
stimulated concentrations two times higher than -GalCer. Moreover, -C-GalCer continued stimulating detectable IL-12 levels 12 h after treatment, whereas by this
time point -GalCer–stimulated IL-12 levels were undetectable (Fig. 4 a). Thus, over time, -C-GalCer stimu-

lated enhanced levels of the Th1 cytokines IFN- and IL12, and diminished levels of the Th2 cytokine IL-4 as
compared with -GalCer, showing that in vivo it does
stimulate an enhanced Th1-type response compared with
-GalCer.
-C-GalCer’s Differential Activity Requires IL-12. Optimal IFN- production by NKT cells requires APCderived IL-12 (2, 4, 9–11). Because -C-GalCer stimulates
much greater IL-12 production than -GalCer (Fig. 4 a),

Figure 5. -C-GalCer’s superior therapeutic activity
against malaria liver stages and melanoma metastases requires
IL-12. (a) WT or IL-12–deficient BALB/c mice were
treated intraperitoneally with 10 ng of either -C-GalCer
or -GalCer or with nothing 3 d before challenge with
live P. yoelii sporozoites, and checked for malaria liver
stage development. (b) WT or IL-12–deficient C57BL/6
mice were treated with 10 ng of either -C-GalCer or
-GalCer or with nothing 2 d before intravenous challenge with 2
105 B16 melanoma cells. 2 wk later, the
lungs were checked for tumor metastases. (a and b) The
results are expressed as the mean
SD of five mice.
The images shown come from one representative mouse
out of five per group.
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we wanted to see if IL-12 is necessary for the difference
between -GalCer– and -C-GalCer–stimulated IFN-
and IL-4 levels (Fig. 4 a). To address this issue, we treated
IL-12–deficient mice with equal doses of either glycolipid,
and at various time points afterwards obtained blood samples for ELISA analyses of IFN- and IL-4 concentrations
in the sera. In the absence of IL-12, IFN- levels were
greatly reduced in both -GalCer– and -C-GalCer–
treated mice, and the difference between the two glycolipids was abrogated (Fig. 4 b). In contrast, IL-4 levels stimulated by -GalCer and -C-GalCer were unaffected in
the absence of IL-12; -GalCer still stimulated roughly
four times more IL-4 than -C-GalCer. Thus, IL-12 affects -GalCer– and -C-GalCer–induced IFN- levels,
but not IL-4.
Because -C-GalCer’s ability to stimulate prolonged
IFN- production is abrogated in the absence of IL-12, we
wanted to see if its superior therapeutic activity against
both malaria liver stages and melanoma metastases to the
lung was abrogated as well. To address this issue, we first
treated both WT and IL-12–deficient mice with equal
doses of either glycolipid 3 d before challenge with sporozoites, and measured malaria liver-stage development. As

expected, in WT mice, -C-GalCer suppressed liver stage
development to a much greater degree than -GalCer;
however, in IL-12–deficient mice, there was no difference
in antimalaria activity between the two glycolipids (Fig. 5
a). Thus, IL-12 is a key factor driving -C-GalCer’s superior antimalaria effect.
Next, to see if IL-12 is also a key factor driving -CGalCer’s superior antimetastatic effect, we treated WT
and IL-12–deficient mice with equal doses of either -CGalCer or -GalCer 2 d before intravenous challenge
with syngeneic melanoma cells; 2 wk later, we checked
the lungs for the number of metastatic nodules that developed. As expected, in WT mice, -C-GalCer better prevented the lungs from melanoma metastases than did
-GalCer; however, in IL-12–deficient mice, there was
no difference in the antimetastatic effect between the two
glycolipids (Fig. 5 b). Thus, as with malaria liver stages,
IL-12 is a key factor driving -C-GalCer’s superior antimetastatic effect.
NK Cells Are the Primary IFN- Source after -GalCer and
-C-GalCer Injection. To determine what cell types are
the principle IFN- sources after -GalCer and -C-GalCer injection, we treated WT mice with equal doses of ei-

Figure 6. NK cells are the primary IFN- source after -GalCer and -C-GalCer injection. WT C57BL/6 mice were treated intraperitoneally with 1 g
of either -GalCer or -C-GalCer, and at various time points afterwards hepatic lymphocytes were obtained and subjected to ICCS. (a) NK1.1 , CD3
NKT cells were gated and analyzed for the presence of intracellular IFN-. (b) NK1.1 , CD3 NKT cells were gated and analyzed for the presence of
intracellular IL-4. (c) NK1.1 , CD3 NK cells were gated and analyzed for the presence of intracellular IFN-. Numbers indicate the percent of cytokinepositive cells in the gated population. The experiments shown are representative of three independent experiments for each staining protocol.
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ther glycolipid, and 2, 6, 12, 24, or 48 h later obtained liver
lymphocytes from the mice for ex vivo ICCS analysis of
IFN-–positive NK (NK1.1 , CD3 ), NKT (NK1.1 ,
CD3 ), T (NK1.1 , CD3 ), and non–T (NK1.1 , CD3 )
cells. At 2 h after injection, a high percentage of NKT cells
from -GalCer–treated mice stained positive for IFN-;
however, at this same time point, very few NKT cells from
mice treated with -C-GalCer stained positive for the cytokine (Fig. 6 a). A similar result was obtained when we
looked at IL-4 production in NKT cells at the 2-h time
point; a high percentage of NKT cells from -GalCer–
treated mice stained positive for IL-4, but very few stained
positive from the -C-GalCer–treated mice (Fig. 6 b). Interestingly, at 6 h after injection, the numbers of NKT cells
were reduced in both -GalCer– and -C-GalCer–treated
mice (Fig. 6, a and b), and remained that way up to the 48-h
time point (not depicted), indicating that over time NKT
cells are not the major IFN- source after administration of
-GalCer and -C-GalCer.
In contrast to NKT cells, NK cells from both -GalCer– and -C-GalCer–treated mice stained positive for
IFN- at time points later than 2 h after injection. In
-GalCer–treated mice, high percentages of NK cells stained
positive for IFN- at 2, 6, and 12 h after injection, returning to low levels by 24 h. In -C-GalCer–treated mice,

the pattern was different, with high percentages of NK
cells staining positive for IFN- at 6, 12, and 24 h after injection, returning to low levels by 48 h (Fig. 6 c). Interestingly, these patterns of NK cell IFN- production correlate closely with the serum IFN- profiles induced by the
glycolipids (Fig. 4 a), strongly suggesting that NK cells are
the principal IFN- sources after -GalCer and -C-GalCer administration. Importantly, no IFN- staining was
observed in NK1.1 , CD3 T cells and NK1.1 , CD3
non–T cells at any time point (unpublished data), further
attesting to the important role of NK cells in glycolipidinduced IFN- production.
Optimal IFN- Production by NK Cells after -GalCer and
-C-GalCer Administration Requires IL-12. To see how
IL-12 affects IFN- production by NK and NKT cells after -GalCer and -C-GalCer injection, we repeated the
ICCS kinetics experiment detailed in the preceding paragraphs, this time using IL-12–deficient mice. At 2 h after
injection, we observed a smaller percentage of IFN-–
positive NKT cells in both -GalCer– and -C-GalCer–
treated IL-12–deficient mice than in WT mice; however,
there were still more IFN-–positive NKT cells in the
-GalCer–treated IL-12–deficient mice than those treated
with -C-GalCer (Fig. 7 a). At 6 h after injection, just
like in WT mice, NKT cell numbers were greatly reduced

Figure 7. Optimal IFN- production by NK
cells after -GalCer and -C-GalCer administration
requires IL-12. IL-12–deficient C57BL/6 mice
were treated intraperitoneally with 1 g of either
-GalCer or -C-GalCer, and at various time
points afterwards liver lymphocytes were obtained
and subjected to ICCS. (a) NK1.1 , CD3 NKT
cells were gated and analyzed for the presence of
intracellular IFN-. (b) NK1.1 , CD3 NK cells
were gated and analyzed for the presence of intracellular IFN-. Numbers indicate the percent of
cytokine-positive cells in the gated population. The
experiments shown are representative of two independent experiments for each staining protocol.
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in both -GalCer– and -C-GalCer–treated IL-12–deficient mice, and remained so up to the 48-h time point.
Thus, IL-12 does appear to facilitate IFN- production by
NKT cells, but it is not an absolute requirement, and does
not appear to seriously affect NKT cell survival after glycolipid injection.
In contrast to NKT cells, NK cell production of IFN-
was severely affected by the lack of IL-12. In both -GalCer– and -C-GalCer–treated IL-12–deficient mice, the
numbers of IFN-–positive NK cells were markedly reduced at all time points as compared with WT mice (Fig. 7
b). This reduction in NK cell IFN- in IL-12–deficient
mice closely parallels the reduced serum IFN- induced by
the glycolipids in these same mice (Fig. 4 b). Thus, IL-12
produced in response to -GalCer and -C-GalCer injection appears to act primarily on NK cells, which respond
by producing the bulk of the IFN- that follows glycolipid
administration.

Discussion
In the current work, we synthesized a C-glycoside analogue of the NKT cell ligand -GalCer, which we refer to
as -C-GalCer. Structurally, -C-GalCer differs from
-GalCer only in the identity of the chemical group involved in the glycosidic linkage between the galactose and
ceramide moieties of the molecule; -C-GalCer’s glycosidic linkage involves a CH2 group, whereas -GalCer’s
glycosidic linkage involves an O atom. Despite this small
difference, we found that the biological activities of the
two molecules differ greatly.
To assess the biological activity of -C-GalCer, and
compare it with that of -GalCer, first we used a murine
malaria model. In a previous paper, we showed that -GalCer can protect mice from the liver stages of malaria when
administered before live sporozoite challenge, and that this
protection requires CD1d presentation of -GalCer,
V14 NKT cell activation, and IFN- production (23).
In the current work, we show that -C-GalCer can also
protect mice from liver-stage malaria when administered
before sporozoite challenge, and that this protection also
requires CD1d presentation of the glycolipid, V14 NKT
cell activation, and IFN- production. Moreover, we
found that -C-GalCer exhibited a much more potent and
longer-lasting anti–liver-stage activity compared with
-GalCer, and that this translated into superior protection
against sporozoite-induced blood-stage infection.
Although the malaria model we used to compare the activities of both -C-GalCer and -GalCer provided a
well-understood, uncomplicated system that yielded clear
results showing a striking difference between the two glycolipids, the potential practicality of using either -C-GalCer or -GalCer against the liver stages of malaria in humans is severely limited because of the need to administer
the glycolipids before sporozoite exposure. At best, the glycolipids might be used for short-term prophylaxis against
malaria, or as a possible therapy for the hypnozoite stage of
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Plasmodium vivax. To see if -C-GalCer has therapeutic efficacy in a more practicable disease system, we used a melanoma lung metastasis model because cancer metastases are
one of the disease states it is hoped -GalCer will one day
treat (4). It has been shown in a previous paper that -GalCer is able to prevent melanoma metastases to the lungs of
mice in a manner dependent on IFN- (26). Because -CGalCer better protects mice from malaria liver stages, and
because this effect requires IFN-, we expected -C-GalCer to exhibit a superior antimetastatic effect compared
with -GalCer as well. Indeed, when administered before
challenge with melanoma cells (i.e., before the metastatic
event), -C-GalCer exhibited a much more potent prophylactic activity against metastasis than -GalCer. Thus,
in two different disease models requiring IFN- for control, -C-GalCer displayed far superior therapeutic activity
than -GalCer.
-C-GalCer’s superior therapeutic activity is probably
due to its ability to stimulate an enhanced Th1-type response relative to that stimulated by -GalCer. After injection into mice, -C-GalCer induced prolonged production of the Th1 cytokines IFN- and IL-12 and decreased
production of the Th2 cytokine IL-4 compared with
-GalCer. It is likely that the increased amount of IFN-
resulting from its prolonged production after -C-GalCer
injection is the main reason for -C-GalCer’s enhanced
potency against malaria liver stages and melanoma metastases, as well as its longer-lasting activity against malaria
liver stages. This assertion is supported by the fact that
-C-GalCer’s superior activity against both malaria liver
stages and melanoma metastases is abrogated in the absence
of IL-12, as is its ability to stimulate prolonged IFN- production relative to -GalCer. The importance of IL-12 for
optimal stimulation of IFN- production by -C-GalCer
and -GalCer suggests that it is -C-GalCer’s ability to
stimulate prolonged IL-12 that allows for its ability to stimulate prolonged IFN- as well. The fact that peak IL-12
production precedes peak IFN- production is consistent
with this conclusion. Interestingly, stimulation of IL-4 production by -C-GalCer and -GalCer is unaffected in the
absence of IL-12. This result makes sense inasmuch as peak
IL-4 production occurs before peak IL-12 production. Because peak IL-4 production precedes peak IL-12 and IFN-
production, it is possible that -C-GalCer’s ability to stimulate decreased IL-4 early on somehow allows for the later
prolonged production of IL-12 and IFN-. Further experiments are needed to resolve this issue.
It is generally believed that by 6 h after stimulation with
-GalCer, NKT cells die by apoptosis (2, 4, 5), although
one very recent paper suggests that NKT cells may not die
after in vivo stimulation with -GalCer (27). It is also
known that downstream of NKT cell activation, NK cells
are stimulated to both proliferate and secrete IFN- (2, 4,
6, 7). Because most of the IFN- produced after -GalCer
treatment appears 12 h after injection, it is likely that most
of this IFN- is provided by NK cells. Indeed, our WT
ICCS results showed that in -GalCer–treated mice, NKT
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cells were a major source of IFN- only at the 2-h time
point after injection because by 6 h they disappeared. In
contrast, NK cells were the principal cell type producing
IFN- 6 and 12 h after -GalCer injection, the very time
points when the level of -GalCer-induced serum IFN-
was highest, and they also provided some of the IFN- 2 h
after injection. In addition, our ICCS data showed that NK
cells were also the primary IFN- source in mice treated
with -C-GalCer. NK cells from -C-GalCer–treated
mice produced most of their IFN- 6, 12, and 24 h after
injection, which overlaps closely with the serum IFN-
profile induced by -C-GalCer. Our results also showed
that -C-GalCer stimulated very few IFN-–producing
NKT cells, although it did induce NKT cell disappearance
in a manner comparable to -GalCer. Thus, NK cells are
the major IFN- source after administration of -GalCer
and -C-GalCer.
As discussed before, optimal IFN- production after either -GalCer or -C-GalCer injection requires the appearance of IL-12. IL-12 is a known stimulator of NK cell
proliferation and IFN- production (28). In addition, a
recent paper has demonstrated a major contribution of
NK cells to IFN- production after NKT cell stimulation
by -GalCer that is dependent on IL-12 signaling (29). In
light of these facts, we examined whether the lack of IL12 affected the ability of NK and NKT cells to produce
IFN- in response to -GalCer and -C-GalCer administration. Our ICCS experiment using IL-12–deficient
mice showed that the lack of IL-12 attenuated the number
of IFN-–positive NKT cells stimulated by either -GalCer or -C-GalCer, but did not affect the survival of
these cells. More importantly, the lack of IL-12 severely
affected the ability of NK cells to produce IFN- after injection of either glycolipid, showing that IL-12 produced
in response to -GalCer and -C-GalCer acts on NK
cells to stimulate downstream IFN-. The likely source of
this IL-12 is probably DCs. DCs are known to express
CD1d on their surface, present -GalCer to NKT cells,
and produce IL-12 in response to this presentation (2, 4,
9–11, 17). Thus, it is likely that DCs are the APCs responsible for presenting -GalCer and -C-GalCer to
NKT cells in vivo, and that -C-GalCer somehow stimulates more IL-12 from DCs after interaction with NKT
cells. Further research is needed to clarify the role of DCs
in -C-GalCer’s in vivo effect, and how exactly -CGalCer stimulates enhanced IL-12.
An important question remains as to exactly why -CGalCer, which differs structurally from -GalCer only
slightly, exhibits such striking biological differences. In all
likelihood, the differences stem from altered binding of
-C-GalCer to CD1d as compared with that of -GalCer.
Such altered binding would likely result in differential recognition of the CD1d–-C-GalCer complex by the TCR
of V14 NKT cells and qualitatively different signal transduction events in both NKT cells and DCs. Such differential signal transduction would result in the altered response
characterized by low IL-4 and prolonged IL-12 and IFN-
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production. The lone difference between -C-GalCer and
-GalCer involves the replacement of -GalCer’s glycosidic O, a polar hydrogen bond acceptor, with CH2, a nonpolar group incapable of participating in hydrogen bonds.
This change in hydrogen bonding capacity might cause
-C-GalCer to sit differently in the CD1d binding pocket
as compared with -GalCer, resulting in an altered structure of the CD1d–-C-GalCer complex and a change in
its affinity with the NKT cell’s TCR. In addition, the CH2
group of -C-GalCer allows for freer rotation about the
axis of the glycosidic bond between the galactose and ceramide than -GalCer’s O. This change might also influence the conformation of -C-GalCer in the CD1d binding pocket, and thereby affect the interaction with the
NKT cell’s TCR. In effect, -C-GalCer might be acting
in a manner similar to altered peptide ligands, conventional
T cell epitopes bearing changes in certain important amino
acid residues that lead to an alteration in the TCR recognition of the peptide–MHC complex, and a differential functional response in the responding T cell (30). Our ICCS
results showing lower numbers of both IFN-–positive and
IL-4–positive NKT cells 2 h after administration of -CGalCer, as compared with -GalCer, strongly suggest that
the signal conveyed by -C-GalCer to NKT cells is indeed
of a different nature than that conveyed by -GalCer. It
also shows, in agreement with a recent paper using -GalCer (29), that -C-GalCer does not polarize NKT cells in
either the Th1 or Th2 direction, but instead seems to provide a weaker stimulus for NKT cell cytokine production
than -GalCer. Given the differential activity stimulated by
-C-GalCer, it might be possible to synthesize other analogues of -GalCer that can stimulate altered NKT cell responses, which might be potentially useful for treatment of
certain diseases.
Overall, we have demonstrated that -C-GalCer is an
NKT cell ligand in vivo that stimulates enhanced Th1type activity compared with -GalCer. Due to the conserved nature of NKT cell responses in mammals, it is
likely that -C-GalCer, which stimulates V14 NKT
cells in mice, also stimulates V24 NKT cells in humans
(31). In this light, if NKT cell–directed therapy ever
comes to fruition in humans, -C-GalCer’s Th1-enhancing activity makes it an excellent chemotherapeutic candidate for a number of human diseases, including cancer metastases, allergy, and various infectious diseases such as
hepatitis B and C (4). Given the fact that recent clinical
trials have shown that -GalCer appears to have biological
activity in cancer patients (32, 33), -C-GalCer has promise as a therapeutic agent.
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